Drugs / Ad35.CS.01
Ad35.CS.01
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01018459 | Apr 2010 → Dec 2011 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00371189 | Jan 2007 → Jun 2014 | Plasmodium falciparum malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01397227 | Jun 2011 → May 2012 | malaria | Crucell Holland BV | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT01366534 | Aug 2011 → Feb 2012 | malaria | GlaxoSmithKline | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad35.CS.01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00371189 ↗ |
| Known as | Ad35.CS.01 Circumsporozoite Malaria Vaccine | “Ad35.CS.01 Circumsporozoite Malaria Vaccine” NCT00371189 ↗ |
| Known as | Adenovirus Type 35 Circumsporozoite Malaria Vaccine | “Adenovirus Type 35 Circumsporozoite Malaria Vaccine (Ad35.CS.01); administered at 0, 1, and 6 months; dosage levels: 10\^8 viral particles (vp)/mL, 10\^9 vp/mL, 10\^10 vp/mL...” NCT00371189 ↗ |
| Modality | Vaccine | “Adenovirus Type 35 based circumsporozoite malaria vaccine” NCT00371189 ↗ |
| Route | Intramuscular | “Adenovirus Type 35 circumsporozoite malaria vaccine (Ad35.CS.01) or normal saline placebo control by the intramuscular route” NCT00371189 ↗ |